Author, as appears in the article.: Castillón, S. García Fernández, J.M. Ortiz Mellet, C. Díaz, Y. Suzuki, Y. Ohno, K. Nanba, E. Higaki, K. Rísquez, R. Castilla, J.
Papper version: info:eu-repo/semantics/submittedVersion
Department: Enginyeria Química
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Abstract: Pyranoid-type glycomimetics having a cis-1,2-fused glucopyranose-2-alkylsulfanyl-1,3-oxazoline (Glc-PSO) structure exhibit an unprecedented specificity as inhibitors of mammalian ß-glucosidase. Notably, their inhibitory potency against human ß-glucocerebrosidase (GCase) was found to be strongly dependent on the nature of aglycone-type moieties attached at the sulfur atom. In the particular case of ?-substituted hexadecyl chains, an amazing influence of the terminal group was observed. A comparative study on a series of Glc-PSO derivatives suggests that hydrogen bond acceptor functionalities, e.g. fluoro or methyloxycarbonyl, significantly stabilize the Glc-PSO:GCase complex. The S-(16-fluorohexadecyl)-PSO glycomimetic turned out to be a more potent GCase competitive inhibitor than ambroxol, a non glycomimetic drug currently in pilot trials as a pharmacological chaperone for Gaucher disease. Moreover, the inhibition constant increased by one order of magnitude when shifting from neutral (pH 7) to acidic (pH 5) media, a favorable characteristic for a chaperone candidate. Indeed, the fluoro-PSO derivative also proved superior to ambroxol in mutant GCase activity enhancement assays in N370S/N370S Gaucher fibroblasts. The results presented here represent a proof of concept of the potential of exploiting long-range non-glycone interactions for the optimization of glycosidase inhibitors with chaperone activity.
Entity: Universitat Rovira i Virgili.
Journal publication year: 2015
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 0223-5234
First page: 258
Last page: 266
Journal volume: 90
Repositori URV